Gender Solutions Natural-Knee Flex

Asymmetric Tibial Trays

  • Zimmer was first to market the innovative asymmetric baseplate design
  • Matching the asymmetric tibial shape provides cortical coverage and helps avoid overhang and soft tissue impingement
  • Deep, beveled posterior notch helps to prevent impingement of the PCL
  • Spiked keel design provides bone-sparing fixation; smooth pegs offer rotational stability

Cancellous-Structured Titanium (CSTi™) Porous Coating

  • CSTi porous coating option for stable fixation in active patients
  • Combines the excellent biocompatibility of titanium with an optimal structure for biological fixation
  • Interconnected pores1 resemble human cancellous bone and fine micro-roughness provides enhanced fixation

Ultracongruent Tibial Articular Surface

  • Gender Solutions Natural-Knee Flex System includes an ultracongruent tibial articular surface
  • This ultracongruent tibial articular surface has published long-term clinical results2 that demonstrate its viability as an alternative to traditional posterior stabilizing designs
  • Allows for easy intraoperative conversion from a PCL-retaining to a PCL-sacrificing solution
  • Maximum intraoperative flexibility with minimized bone loss

Two Distinct Shapes for Men and Women

  • Industry-leading Gender Solutions technology
  • Proven success of the Natural-Knee System
  • Innovative high-flex designs
  • Zimmer was the first to recognize that when it comes to knees, men and women are different. Our groundbreaking research demonstrated that the differences are less about size—and more about shape. Now, Zimmer is applying industry-leading Gender Solutions technology to the clinically successful Natural-Knee System3. The future of total knee arthroplasty is here: the all-new Zimmer Gender Solutions Natural-Knee Flex System.

References

  1. Bobyn JD, Pilliar RM, Cameron HU, Weatherby GC. The Optimum Pore Size for the Fixation ofPorous-Surfaced Metal Implants by the Ingrowth of Bone. Clin Orthop. 1980, 150:263-70.
  2. Hofmann A, Tkach T, Evanich C, Camargo P. Posterior Stabilization in Total Knee Arthroplasty With Use of an Ultracongruent Polyethylene Insert. Journal of Arthroplasty. 2000; 15 (5), 576-583.
  3. Hofmann AA, Evanich, JD, Ferguson, RP, Camargo, MP. Ten- to 14-year clinical follow-up of thecementless Natural-Knee system. Clin Orthop. July, 2001; (388): 85-94.

    4.  

Technology

Technology

Gender Solutions Technology

High Flex Technologies

MIS Instruments

Highly Crosslinked Polyethylene

Congruent and ultracongruent articular surfaces

PSI

Related Products

Related Products

Natural-Knee II System

NexGen® CR Flex- Compatibility

Product Evolution

  • 1985 October, Multi-center FDA Trial Natural-Knee I System
  • 1986 Natural-Knee I System introduction to US Market
  • 1990 Natural-Knee I System CoCr femoral components replace Ti femoral components
  • 1992 Ultracongruent tibial insert introduction
  • 1995 Launch of Natural-Knee II Primary and Revision system
  • 1997 Natural-Knee II Primary system receives PMA for cementless application
  • 1998 Constrained/Revision System Introduction
  • 2000 Introduction of the Rotating Platform of NK II in Europe
  • 2001 Natural-Knee II Durasul® Polyethylene Introduction
  • 2005 MIS Instrumentation
  • 2008 Gender Solutions Natural-Knee Flex System
  • 2008 Introduction of Prolong Highly Crosslinked Polyethylene option
Previous page
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.  
This material is intended for health care professionals. Distribution to any other recipient is prohibited.
For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and information on this website. To obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please call 1-800-348-2759, press 4 for 411 Technical Support.